Androgens' Role in Severity and Mortality Rates of COVID-19

October 2022 in “ Hormone and Metabolic Research ”

Ali Ataei, Mohammad Moein Derakhshan, mohadese razmjooie, Fateme Zare, habibe Amiresmaeili, Negin Salehi, Negar Namakkoobi, Hamid Mirhosseini, Bardia Karim, sima iravani

Studysummary This review discusses the significant role androgens may play in COVID-19 severity and mortality, but it reports no new results; further research in diverse populations is needed.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

We don't know much about this study yet.

View this study on thieme-connect.de →

Discuss this study in the Community →

Research cited in this study

18 / 18 results

Final Results of a Randomized, Placebo-Controlled, Two-Arm, Parallel Clinical Trial of Proxalutamide for Hospitalized COVID-19 Patients: A Multiregional, Joint Analysis of the Proxa-Rescue AndroCoV Trial

research Final Results of a Randomized, Placebo-Controlled, Two-Arm, Parallel Clinical Trial of Proxalutamide for Hospitalized COVID-19 Patients: A Multiregional, Joint Analysis of the Proxa-Rescue AndroCoV Trial

19 citations , December 2021 in “Cureus”

This study found that proxalutamide significantly increased recovery rates, reduced mortality, and shortened hospital stays in hospitalized COVID-19 patients across different regions in Brazil.

research Association of Androgenetic Alopecia and Severity of Coronavirus Disease 2019

4 citations , December 2021 in “Journal of Cosmetic Dermatology”

This observational study found a significant association between the severity of androgenetic alopecia and worse COVID-19 outcomes in men compared to women, suggesting potential value in anti-androgen treatments.

research SARS-CoV-2 Spike Protein S1-Mediated Endothelial Injury and Pro-Inflammatory State Is Amplified by Dihydrotestosterone and Prevented by Mineralocorticoid Antagonism

50 citations , November 2021 in “Viruses”

This study observed that in vitro exposure to dihydrotestosterone worsened COVID-19 spike protein-induced endothelial injury, while spironolactone showed potential in reducing this effect, suggesting a rationale for further evaluation in treating COVID-19.

Proxalutamide Improves Inflammatory, Immunologic, and Thrombogenic Markers in Mild-to-Moderate COVID-19 Males and Females: An Exploratory Analysis of a Randomized, Double-Blinded, Placebo-Controlled Trial Early Antiandrogen Therapy with Proxalutamide

research Proxalutamide Improves Inflammatory, Immunologic, and Thrombogenic Markers in Mild-to-Moderate COVID-19 Males and Females: An Exploratory Analysis of a Randomized, Double-Blinded, Placebo-Controlled Trial Early Antiandrogen Therapy with Proxalutamide

5 citations , July 2021 in “medRxiv (Cold Spring Harbor Laboratory)”

This study found that proxalutamide improved immunologic, inflammatory, thrombotic, and oxygen markers in both female and male COVID-19 outpatients, which may support its association with lower hospitalization rates compared to standard care.

Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial

research Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial

42 citations , July 2021 in “Frontiers in Medicine”

In this study, proxalutamide significantly reduced the 30-day hospitalization rate by 91% compared to placebo in men with COVID-19 treated in outpatient settings.

Proxalutamide Reduction of Mortality Rate in Hospitalized COVID-19 Patients Depends on Treatment Duration – An Exploratory Analysis of the Proxa-Rescue AndroCoV Trial

research Proxalutamide Reduction of Mortality Rate in Hospitalized COVID-19 Patients Depends on Treatment Duration – An Exploratory Analysis of the Proxa-Rescue AndroCoV Trial

5 citations , July 2021 in “bioRxiv (Cold Spring Harbor Laboratory)”

This study found that a 14-day treatment with proxalutamide significantly reduced the 28-day mortality rate in hospitalized COVID-19 patients compared to placebo, with greater benefits observed among those who adhered to the treatment.

research The Antiandrogen Enzalutamide Downregulates TMPRSS2 and Reduces Cellular Entry of SARS-CoV-2 in Human Lung Cells

50 citations , July 2021 in “Nature Communications”

This study found that the antiandrogen drug enzalutamide reduced TMPRSS2 levels and significantly decreased SARS-CoV-2 entry and infection in lung cells, supporting further clinical trials for COVID-19 treatment.

research Do Anti-Androgens Have Potential as Therapeutics for COVID-19?

18 citations , June 2021 in “Endocrinology”

This review discusses the link between androgen receptor action and TMPRSS2 expression in severe COVID-19, exploring the potential of anti-androgens to mitigate disease severity in men and notes ongoing trials.

research Expression of Concern: Potential Risk for Developing Severe COVID-19 Disease Among Anabolic Steroid Users

21 citations , February 2021 in “BMJ case reports”

This case study potentially links the use of anabolic steroids to increased severity of COVID-19 in a healthy 28-year-old man, with marked symptom improvement following treatment with proxalutamide.

research Anti-Androgens May Protect Against Severe COVID-19 Outcomes: Results From a Prospective Cohort Study of 77 Hospitalized Men

49 citations , January 2021 in “Journal of The European Academy of Dermatology and Venereology”

Anti-androgens, like finasteride, dutasteride, and spironolactone, may lessen the severity of COVID-19 in men, leading to fewer ICU admissions.

research 5-Alpha-Reductase Inhibitors Are Associated With Reduced Frequency of COVID-19 Symptoms in Males With Androgenetic Alopecia

36 citations , November 2020 in “Journal of The European Academy of Dermatology and Venereology”

This study found that 5-alpha-reductase inhibitors were associated with a reduced frequency of COVID-19 symptoms in males with androgenetic alopecia.

research Clinical Symptoms of Hyperandrogenic Women Diagnosed with COVID-19

29 citations , October 2020 in “Journal of the European Academy of Dermatology and Venereology”

This article is a discussion piece that examines the clinical symptoms of hyperandrogenic women with COVID-19, without reporting new research findings.

An Open-Label Prospective Observational Study of Antiandrogen and Non-Antiandrogen Early Pharmacological Approaches in Females with Mild-to-Moderate COVID-19: The Pre-AndroCoV Female Trial

research An Open-Label Prospective Observational Study of Antiandrogen and Non-Antiandrogen Early Pharmacological Approaches in Females with Mild-to-Moderate COVID-19: The Pre-AndroCoV Female Trial

6 citations , October 2020 in “medRxiv (Cold Spring Harbor Laboratory)”

This study found that early pharmacological treatment of COVID-19 in females, including those with hyperandrogenic conditions, significantly improved clinical outcomes, with spironolactone users experiencing milder symptoms and faster recovery.

Androgen Receptor Genetic Variant Predicts COVID-19 Disease Severity: A Prospective Longitudinal Study of Hospitalized COVID-19 Male Patients

research Androgen Receptor Genetic Variant Predicts COVID-19 Disease Severity: A Prospective Longitudinal Study of Hospitalized COVID-19 Male Patients

26 citations , September 2020 in “Journal of the European Academy of Dermatology and Venereology”

This publication is a letter discussing the association between an androgen receptor genetic variant and COVID-19 disease severity in hospitalized male patients, but it reports no new research results.

research Androgen Deprivation Therapy May Be a More Effective COVID-19 Prophylactic Than Therapeutic Strategy

12 citations , August 2020 in “Annals of Oncology”

This study found that androgen deprivation therapy in prostate cancer patients was associated with fewer SARS-CoV-2 infections but did not reduce COVID-19 disease severity or hospitalizations.

research Gender Differences in Patients With COVID-19: A Narrative Review

91 citations , May 2020 in “Monaldi Archives for Chest Disease”

This narrative review explores gender differences in the epidemiology, risk factors, and effects of COVID-19, emphasizing the need for further analysis using comprehensive gender indicators to shape effective public health strategies and policies.

A Preliminary Observation: Male Pattern Hair Loss Among Hospitalized COVID-19 Patients in Spain – A Potential Clue to the Role of Androgens in COVID-19 Severity

research A Preliminary Observation: Male Pattern Hair Loss Among Hospitalized COVID-19 Patients in Spain – A Potential Clue to the Role of Androgens in COVID-19 Severity

134 citations , April 2020 in “Journal of Cosmetic Dermatology”

Male pattern hair loss could hint at androgens affecting COVID-19 severity.

research The North American Menopause Society Recommendations for Clinical Care of Midlife Women

254 citations , September 2014 in “Menopause”

The NAMS 2014 recommendations guide healthcare providers on treating health issues in midlife women, emphasizing individualized care and informed decision-making.